XBP1 and diabetic kidney disease: A number of groups have synthesized small molecules that block IRE-1α activity and splicing of XBP-1 [181,182,183,184,185] for use in multiple myeloma and chronic lymphocytic leukemia, however their effect on diabetic nephropathy is unpredictable.